---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-25-000037"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:35:26.306372+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Altimmune's pemvidutide Phase 2b MASH trial hits primary endpoint; 59.1% resolution vs 19.1% placebo (p<0.0001)

## Summary
- MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).
- Fibrosis improvement not significant on primary, but AI analysis showed 30.6% achieving ≥60% reduction (p<0.001).
- Weight loss of 5.0% (1.2mg) and 6.2% (1.8mg) vs 1.0% placebo (p<0.001); trajectory not plateauing at 24 weeks.
- AE-related discontinuations <1.2% in pemvidutide arms vs 2.4% placebo; no SAEs related to study drug.

## SEC filing metadata
- accession: 0001326190-25-000037
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/0001326190-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/alt-20250626x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-25-000037
- JSON: https://secwatch.observer/filing/0001326190-25-000037.json
- Plain text: https://secwatch.observer/filing/0001326190-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.